Calpine (CPN) to Acquire 809-MW Plant from Exelon (EXC) in $530M Deal
Get Alerts CPN Hot Sheet
Join SI Premium – FREE
Calpine (NYSE: CPN) announced that it has agreed to purchase a nominal 809 megawatt, combined-cycle power plant and related plant inventory from Exelon Corporation (NYSE: EXC) for $530 million, or approximately $655 per kilowatt, subject to working capital adjustments. The natural gas-fired plant is located in North Weymouth, Massachusetts, 12 miles southeast of Boston, and expands Calpine’s footprint in the New England competitive wholesale power market.
“With the acquisition of Fore River, we will grow our presence in a region that features favorable fundamentals and a supportive, market-based regulatory philosophy,” said Calpine’s President and Chief Executive Officer Thad Hill. “This modern, efficient power plant is dual-fuel capable, making it an excellent fit with our existing, reliable East Region fleet. We continue to redeploy our capital to enhance shareholder value through accretive acquisitions and divestitures, organic growth, balance sheet management and return of capital to shareholders through our share repurchase program.”
Built in 2003, Fore River Generating Station features two Mitsubishi 501G combustion turbines, two heat recovery steam generators and one Mitsubishi steam turbine. The plant’s dual-fuel capability enables it to run on either natural gas or fuel oil, depending upon market conditions.
Calpine expects the transaction to close in the fourth quarter of 2014 and intends to fund the transaction with cash on hand. The transaction is subject to customary closing conditions, antitrust review under the Hart-Scott-Rodino Act and FERC approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uniti Group (UNIT), Windstream Said To Near $15 Billion Combination - Bloomberg
- Infinite Reality Acquires the Drone Racing League for $250 Million, Solidifying Position as Global Leader in Immersive Technology & Experiences (NBST)
- Incyte (INCY) Announces Acquisition of Escient Pharmaceuticals
Create E-mail Alert Related Categories
Guidance, Management Comments, Mergers and AcquisitionsRelated Entities
Stock Buyback, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!